文献速递糖尿病

苏格兰全国观察性研究:1型糖尿病起始胰岛素泵治疗后血糖结局显著改善

Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland.
PubMed 文献 · Diabetologia · 2021-03-08

该研究基于苏格兰全国登记数据,纳入2004至2019年间起始持续皮下胰岛素输注(CSII)的4684例1型糖尿病患者。结果显示CSII起始后HbA1c中位下降5.5 mmol/mol,基线HbA1c最高者降幅最大且长期维持;CSII与DKA及严重住院低血糖事件率下降独立相关。

要点

  • CSII起始后HbA1c中位下降5.5 mmol/mol,基线HbA1c最高者获益最大
  • 基线HbA1c>84 mmol/mol者1年内中位下降21.0 mmol/mol,≥5年仍维持
  • CSII与DKA和严重住院低血糖事件率下降独立相关

核心结论

  • CSII治疗与HbA1c显著下降相关,尤其在基线HbA1c高者中更为明显。
  • CSII与DKA发生率下降独立相关。
  • CSII与严重住院低血糖发生率下降独立相关。
  • CSII可能是改善血糖控制不佳的1型糖尿病患者强化胰岛素治疗的有效选择。

研究设计与样本

  • 全国性观察性研究,数据来自苏格兰全国登记。
  • 纳入2004至2019年间起始CSII的4684例1型糖尿病患者。
  • 分析起始后HbA1c的个体内变化及CSII暴露前后的DKA与SHH粗事件率。
  • 采用混合模型评估CSII暴露的显著性,并考虑干预的弥漫性、重复测量及干预前背景时间趋势。

主要发现

  • CSII起始后HbA1c下降,个体内变化中位数为-5.5 mmol/mol(IQR -12.0, 0.0),即-0.5%(IQR -1.1, 0.0)。
  • 基线HbA1c>84 mmol/mol(9.8%)者暴露1年内中位变化为-21.0 mmol/mol(-30.0, -11.0),即-1.9%(-2.7, -1.0)。
  • 上述高基线人群在≥5年时仍维持下降:-19.0 mmol/mol(-27.6, -6.5),即-1.7%(-2.5, -0.6)。
  • CSII后DKA粗事件率为49.6/1000人年(95%CI 46.3, 53.1),低于CSII前的67.9/1000人年(64.1, 71.9)。
  • CSII后SHH粗事件率为17.8/1000人年(95%CI 15.8, 19.9),低于CSII前的25.8/1000人年(23.5, 28.3)。

关键数值与推荐

  • DKA率比(贝叶斯混合模型校正暴露前趋势):0.61(95%可信区间0.47, 0.77;下降后验概率pp=1.00)。
  • SHH率比(贝叶斯混合模型校正暴露前趋势):0.67(95%可信区间0.45, 1.01;pp=0.97)。
  • HbA1c中位个体内变化:-5.5 mmol/mol(IQR -12.0, 0.0),即-0.5%(IQR -1.1, 0.0)。
  • 基线HbA1c>84 mmol/mol(9.8%)者1年内中位变化-21.0 mmol/mol(-30.0, -11.0),即-1.9%(-2.7, -1.0)。

临床怎么用

  • 对血糖控制不佳的1型糖尿病患者,CSII可作为强化胰岛素治疗的有效选择。
  • 基线HbA1c较高者起始CSII后血糖改善幅度更大且可长期维持。
  • 起始CSII可能同时有助于降低DKA与严重住院低血糖风险。

局限性

  • 为观察性研究,无法完全排除残余混杂。
  • 原文摘要未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Our aim was to assess the use of continuous subcutaneous insulin infusion (CSII) in people with type 1 diabetes in Scotland and its association with glycaemic control, as measured by HbA1c levels, frequency of diabetic ketoacidosis (DKA) and severe hospitalised hypoglycaemia (SHH), overall and stratified by baseline HbA1c. METHODS: We included 4684 individuals with type 1 diabetes from the national Scottish register, who commenced CSII between 2004 and 2019. We presented crude within-person differences from baseline HbA1c over time since initiation, crude DKA and SHH event-rates pre-/post-CSII exposure. We then used mixed models to assess the significance of CSII exposure, taking into account: (1) the diffuse nature of the intervention (i.e. structured education often precedes initiation); (2) repeated within-person measurements; and (3) background time-trends occurring pre-intervention. RESULTS: HbA1c decreased after CSII initiation, with a median within-person change of -5.5 mmol/mol (IQR -12.0, 0.0) (-0.5% [IQR -1.1, 0.0]). Within-person changes were most substantial in those with the highest baseline HbA1c, with median -21.0 mmol/mol (-30.0, -11.0) (-1.9% [-2.7, -1.0]) change in those with a baseline >84 mmol/mol (9.8%) within a year of exposure, that was sustained: -19.0 mmol/mol (-27.6, -6.5) (-1.7% [-2.5, -0.6]) at ≥5 years. Statistical significance and magnitude of change were supported by the mixed models results. The crude DKA event-rate was significantly lower in post-CSII person-time compared with pre-CSII person-time: 49.6 events (95% CI 46.3, 53.1) per 1000 person-years vs 67.9 (64.1, 71.9); rate ratio from Bayesian mixed models adjusting for pre-exposure trend: 0.61 (95% credible interval [CrI] 0.47, 0.77; posterior probability of reduction pp = 1.00). The crude overall SHH event-rate in post-CSII vs pre-CSII person-time was also lower: 17.8 events (95% CI 15.8, 19.9) per 1000 person-years post-exposure vs 25.8 (23.5, 28.3) pre-exposure; rate ratio from Bayesian mixed models adjusting for pre-exposure trend: 0.67 (95% CrI 0.45, 1.01; pp = 0.97). CONCLUSIONS/INTERPRETATION: CSII therapy was associated with marked falls in HbA1c especially in those with high baseline HbA1c. CSII was independently associated with reduced DKA and SHH rates. CSII appears to be an effective option for intensive insulin therapy in people with diabetes for improving suboptimal glycaemic control.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Jeyam A, Gibb FW, McKnight JA, et al. Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. Diabetologia. 2021. PMID: 33686483. doi:10.1007/s00125-021-05413-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。